Merus (MRUS)
(Delayed Data from NSDQ)
$65.54 USD
-1.91 (-2.83%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $65.60 +0.06 (0.09%) 7:24 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRUS 65.54 -1.91(-2.83%)
Will MRUS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MRUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRUS
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
MRUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
Other News for MRUS
MRUS: Needham Maintains Buy Rating, Lowers Price Target | MRUS Stock News
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference | MRUS Stock News
Paradigm Biocapital Advisors LP Acquires 1,128,613 Shares in Cidara Therapeutics Inc
Merus (MRUS) Financial Position Strong with Funding Secured Until 2028
Merus (MRUS) Q2 Revenue Falls Short of Expectations, Exciting Clinical Developments Ahead